Colleen Hussey

Corp Comms at Alnylam. Forever a #JHU Blue Jay. Tweets are my own.

[Ronald Witteles @Ron_Witteles]

A monumental day for the #ATTR #amyloidosis field: #Vutrisiran is now FDA approved for ATTR-CM! The landmark #HELIOS-B trial hit 10/10 prespecified endpoints including improved all-cause mortality. Congratulations to everyone who contributed to the development/approval, and a special thanks to all of the patients who participated in the clinical trials. This is how #sciencemovesforward! 🍾https://t.co/9r69ULYrWn

[Alnylam Pharmaceuticals @Alnylam]

This morning, we reported Q4 & full-year 2024 financial results & key updates. Join our LIVE webcast TODAY at 8:30 am ET or catch the replay later: https://t.co/dYwvZeqfiY

Read the full press release: https://t.co/Wox6TC4RVe

#RNAi #siRNA

[Colleen Hussey @CollHuss]

So proud to be a part of the development of this content series about #mRNA! Tune in to learn more about how Moderna is changing the future of medicine

[Moderna @moderna_tx]

For more than a decade, we have been at the forefront of groundbreaking #mRNA research that holds immense potential to revolutionize healthcare. Hear more from @cleoabram about how we are studying mRNA to see if one day it can teach our bodies to make its own #medicine.

[Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC]

Our Dr. Jeffrey Weber spoke with the @WSJ about the promising melanoma research he presented at #AACR23 today. An #mRNA shot & pembro helped prevent relapse in hi-risk patients @moderna_tx @Merck
https://t.co/5H4uccvKeb

[AACR @AACR]

The first study in today’s press conference is presented by Jeffrey Weber, MD, PhD, from NYU Langone Perlmutter Cancer Center, and Ryan Sullivan, MD, from Mass General Cancer Center and Harvard Medical School. #AACR23 https://t.co/IM4hiQ5sTN

[Moderna @moderna_tx]

Today, Moderna and Merck announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen #therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with resected high-risk #melanoma (stage III/IV).

These findings will be presented during the 2023 @AACR Annual Meeting plenary session (Abstract #CT001).

Data from a subgroup analysis of KEYNOTE-942/mRNA-4157-P201 (Abstract #CT224) evaluating mRNA-4157 (V940) in combination with KEYTRUDA among patients based on tumor mutational burden (TMB) status will also be presented.

Learn more: https://t.co/7WMzNKUlsP

#AACR23

[Moderna @moderna_tx]

Today we announced that Phase 2 data on mRNA-4156/V940, our investigational personalized #mRNA #cancer vaccine, will be presented at the 2023 American Association of Cancer Research Annual Meeting being held April 14-19 in Orlando, FL.

mRNA-4157/V940 is being jointly developed by Moderna and @Merck, known as MSD outside of the United States and Canada. Read more: https://t.co/yfNGzAzBbN

#AACR23

[Moderna @moderna_tx]

The last few years have amplified the responsibility of both private and public sectors to address health inequities that were exacerbated by the global #pandemic. When we reflect about what #HealthEquity means to Moderna – it's making sure people of all backgrounds have access to the promising #medicines of tomorrow.

Read more about our commitment to removing barriers to representation in clinical research: https://t.co/mdRk4XqhQS

[Moderna @moderna_tx]

Jordan has Glycogen Storage Disease Type 1a (GSD-1a) - which is a rare inherited metabolic disease that affects just 1 in 1.25 million people. It is caused by an #enzyme deficiency where the liver fails to break down glycogen into #glucose, causing the body’s blood sugar levels to drop.

Moderna is committed to advancing #mRNA research for patients living with #RareDiseases like GSD-1a.

#RareDiseaseDay

[Moderna @moderna_tx]

On @rarediseaseday, Kyle Holen, MD, our SVP and Head of Development, Therapeutics and Oncology shares his motivation and commitment to the #RareDisease community. Read more: https://t.co/UeGf44vhkX

[Moderna @moderna_tx]

One medicine, for one patient. We, along with our partner @Merck, are pioneering a new frontier in the fight against #cancer by designing an mRNA-based investigational personalized cancer #vaccine - that targets each patient’s unique cancer cells. Learn more about how it works ⬇

[Noubar Afeyan @NoubarAfeyan]

10 million people around the world die from cancer each year. For many years, @moderna_tx has pursued the pioneering use of MRNA in treating cancer — today’s news represents a big leap forward in that effort. https://t.co/GqYH62gmy5

[Moderna @moderna_tx]

Stéphane Bancel, our Chief Executive Officer, speaks about mRNA-4157/V940, our investigational personalized #mRNA #cancer #vaccine, and Phase 2b trial results in his latest blog post. Read the full blog here: https://t.co/cL1SRsY0Ho

[Eric Topol @EricTopol]

The 1st randomized trial of an mRNA cancer vaccine to show efficacy: Stage III/IV melanoma, a combination immunotherapy + vaccine was superior to immunotherapy alone for recurrence-free survival.
157 participants (Phase 2b) w/ large trial planned
PR by Moderna & Merck this AM

[Moderna @moderna_tx]

Today, we are highlighting progress on our environmental, social and governance (#ESG) strategy at our first ESG Day.
Read more: https://t.co/USuCDhU8i6

Tune in live at 9 am ET: https://t.co/XgWcetlS2q

[Moderna @moderna_tx]

Thank you @BillieJeanKing for connecting with some of our employees ahead of today’s women’s singles final at the #USOpen2022.

BJK told our team: “Science, like tennis, has no failures. Only feedback.” Here’s to the #ChangeMakers.

[ESPN @espn]

The greatest to ever do it.

Thank you, @serenawilliams ❤️

[Moderna @moderna_tx]

ANNOUNCEMENT 📢: We have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for our BA.4/.5 #Omicron-targeting bivalent #COVID19 booster #vaccine, mRNA-1273.222. Learn more 👇�ANNOUNCEMENT 📢: We have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for our BA.4/.5 #Omicron-targeting bivalent #COVID19 booster #vaccine, mRNA-1273.222. Learn more 👇�ANNOUNCEMENT 📢: We have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for our BA.4/.5 #Omicron-targeting bivalent #COVID19 booster #vaccine, mRNA-1273.222. Learn more 👇�ANNOUNCEMENT 📢: We have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for our BA.4/.5 #Omicron-targeting bivalent #COVID19 booster #vaccine, mRNA-1273.222. Learn more 👇🏽

[Billie Jean King @BillieJeanKing]

Known globally for its COVID-19 vaccine, Moderna is focused on educating the public on the broader promise of mRNA science, and on changing the future of medicine.

I’m honored to be highlighted as a #changemaker in a new video.

Learn more: https://t.co/xiI2P4Js7K.

[Moderna @moderna_tx]

Welcome to the #mRNAge. At Moderna, we’re using our mRNA platform to develop new vaccines and therapeutics that may one day treat diseases and personalize #medicine. See what #mRNA could do at https://t.co/Y83kvLQmge.